Predict your next investment

HEALTHCARE | Drug Development

See what CB Insights has to offer

Founded Year



Acquired | Acquired

Total Raised




About Myonexus Therapeutics

Myonexus Therapeutics is a clinical-stage gene therapy company developing corrective gene therapies for Limb-Girdle muscular dystrophies, debilitating rare diseases with no treatments.

Myonexus Therapeutics Headquarter Location

8000 Walton Parkway

New Albany, Ohio, 43054,

United States


Latest Myonexus Therapeutics News

Sarepta acquires Myonexus, reports LGMD trial results

Mar 4, 2019

Sarepta acquires Myonexus, reports LGMD trial results 12:08 PM PDF Sarepta Therapeutics Inc. (NASDAQ:SRPT) exercised its option to acquire Myonexus Therapeutics Inc. (New Albany, Ohio), giving it a pipeline of five gene therapy candidates to treat forms of limb-girdle muscular dystrophy (LGMD). Sarepta also revealed efficacy data from a Phase I/II trial of one of the candidates, MYO-101, in a cohort of patients with LGMD type 2E; the results exceeded expectations. Sarepta paid $165 million to exercise the buyout option, which it acquired in May 2018 for $60 million up front. Along with the type 2E candidate, Sarepta gains gene therapies to treat LGMD types 2D, 2B, 2C and 2L. Besides MYO-101, two programs have reached the clinic: MYO-102 for... Read the full 530 word article User Sign in

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Myonexus Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Myonexus Therapeutics is included in 3 Expert Collections, including Pharma Startups.


Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.


Regenerative Medicine

1,763 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.